Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in adult Langerhans cell histiocytosis (single-arm phase 2 trial)
2016-003300-31Phase 2Completed
- Sponsor
- Hellenic Society for the Study of Bone Metabolism
- Start
- Mar 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of denosumab in Langerhans cell histiocytosis (LCH), sponsored by Hellenic Society for the Study of Bone Metabolism. Primary endpoint: Primary efficacy endpoint. Started Mar 2017; status: completed.
02
Drugs
denosumab
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on 2016-003300-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003300-31.